Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus.

Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D'Argenio DZ.

CPT Pharmacometrics Syst Pharmacol. 2016 Feb;5(2):65-73. doi: 10.1002/psp4.12058. Epub 2016 Feb 2.

2.

Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses.

Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, Wandersee L, Downs B, Smee DF, Furuta Y, Bray M, Gowen BB.

Antiviral Res. 2016 Feb;126:62-8. doi: 10.1016/j.antiviral.2015.12.006. Epub 2015 Dec 19.

PMID:
26711718
3.

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.

Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Böcher WO, Mensa FJ.

PLoS One. 2015 Dec 9;10(12):e0144004. doi: 10.1371/journal.pone.0144004. eCollection 2015.

4.

ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection.

Maan R, van der Meer AJ, Brouwer WP, Plompen EP, Sonneveld MJ, Roomer R, van der Eijk AA, Groothuismink ZM, Hansen BE, Veldt BJ, Janssen HL, Boonstra A, de Knegt RJ.

PLoS One. 2015 Oct 6;10(10):e0139317. doi: 10.1371/journal.pone.0139317. eCollection 2015.

5.

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.

Pineda-Tenor D, García-Álvarez M, Jiménez-Sousa MA, Vázquez-Morón S, Resino S.

J Transl Med. 2015 Oct 6;13:320. doi: 10.1186/s12967-015-0682-y.

6.

Role of genetic polymorphisms in hepatitis C virus chronic infection.

Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E.

World J Clin Cases. 2015 Sep 16;3(9):807-22. doi: 10.12998/wjcc.v3.i9.807.

7.

Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.

Delvaux N, Costa VD, Costa MM, Villar LM, Coelho HS, Esberard EB, Flores PP, Brandão-Mello CE, Villela-Nogueira CA, Almeida AJ, Lampe E.

Mem Inst Oswaldo Cruz. 2015 Aug;110(5):636-43. doi: 10.1590/0074-02760150104. Epub 2015 Jul 7.

8.

Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.

Rower JE, Meissner EG, Jimmerson LC, Osinusi A, Sims Z, Petersen T, Bushman LR, Wolfe P, McHutchison JG, Kottilil S, Kiser JJ.

J Antimicrob Chemother. 2015 Aug;70(8):2322-9. doi: 10.1093/jac/dkv122. Epub 2015 May 13.

PMID:
25971261
9.

A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.

Naik GS, Tyagi MG.

J Clin Exp Hepatol. 2012 Mar;2(1):42-54. doi: 10.1016/S0973-6883(12)60090-5. Epub 2012 Apr 12. Review.

10.

Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Wu LS, Rower JE, Burton JR Jr, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ.

Antimicrob Agents Chemother. 2015 Apr;59(4):2179-88. doi: 10.1128/AAC.04618-14. Epub 2015 Feb 2.

11.

Pharmacogenomics of antimicrobial agents.

Aung AK, Haas DW, Hulgan T, Phillips EJ.

Pharmacogenomics. 2014;15(15):1903-30. doi: 10.2217/pgs.14.147. Review.

12.

Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.

Hwang JJ, Lo CC, Lin CH, Cheng HS, Hung IW, Tsai WJ, Hung CH.

Gut Liver. 2015 Mar;9(2):214-23. doi: 10.5009/gnl14095.

13.

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.

Aghemo A, Grassi E, Rumi MG, D'Ambrosio R, Galmozzi E, Degasperi E, Castaldi D, Soffredini R, Colombo M.

PLoS One. 2014 Apr 23;9(4):e95881. doi: 10.1371/journal.pone.0095881. eCollection 2014.

14.

Individualization of chronic hepatitis C treatment according to the host characteristics.

Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN.

World J Gastroenterol. 2014 Mar 21;20(11):2839-53. doi: 10.3748/wjg.v20.i11.2839. Review.

15.

Purinergic signalling in the liver in health and disease.

Burnstock G, Vaughn B, Robson SC.

Purinergic Signal. 2014 Mar;10(1):51-70. doi: 10.1007/s11302-013-9398-8. Epub 2013 Nov 24. Review.

16.

Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.

Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, Wyatt C, Odin JA, Liu LU, Schiano TD, Perumalswami PV, Bansal M, Dieterich DT, Branch AD.

Liver Int. 2014 Aug;34(7):1018-24. doi: 10.1111/liv.12342. Epub 2013 Oct 25.

17.

Metabolome analysis of erythrocytes from patients with chronic hepatitis C reveals the etiology of ribavirin-induced hemolysis.

Karasawa T, Saito T, Ueno Y, Sugimoto M, Soga T.

Int J Med Sci. 2013 Sep 9;10(11):1575-7. doi: 10.7150/ijms.6436. eCollection 2013.

18.

ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogenetics.

Simone PD, Pavlov YI, Borgstahl GE.

Mutat Res. 2013 Oct-Dec;753(2):131-46. doi: 10.1016/j.mrrev.2013.08.001. Epub 2013 Aug 19. Review.

19.

Management of anemia in patients receiving triple therapy for hepatitis C.

Barritt AS 4th.

Gastroenterol Hepatol (N Y). 2013 May;9(5):314-6. No abstract available.

20.

Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy.

Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M.

World J Gastrointest Pharmacol Ther. 2013 Aug 6;4(3):54-60. doi: 10.4292/wjgpt.v4.i3.54.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk